Literature DB >> 14644242

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease.

Rafael E Andrade1, Michel E Farah, Rogério A Costa.   

Abstract

PURPOSE: To describe the effects of photodynamic therapy using verteporfin for the treatment of subfoveal choroidal neovascularization (CNV) in Best vitelliform macular dystrophy.
DESIGN: Interventional case report.
METHODS: A 43-year-old patient with confirmed Best vitelliform macular dystrophy complicated with subfoveal CNV received a single photodynamic therapy session with verteporfin. The patient was prospectively followed with fluorescein angiography and optical coherence tomography.
RESULTS: A regression of the neovascular lesion and resolution of the exudative manifestations was observed 3 weeks after treatment; at that time, visual acuity had improved from 20/60 to 20/25. Optical coherence tomography disclosed restoration of normal macular architecture due to fluid resolution and lesion contraction. Up to 2 years from this single treatment, no further change was observed.
CONCLUSIONS: Regression of CNV and resolution of subretinal hemorrhage as well as exudative manifestations occurred after photodynamic therapy with verteporfin. Verteporfin therapy may be a viable treatment for subfoveal neovascular lesions in Best vitelliform macular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644242     DOI: 10.1016/s0002-9394(03)00711-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

2.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

3.  [Statement from the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration : October 2017].

Authors: 
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

4.  Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment.

Authors:  Tie-Zhu Lin; Emmanuel Eric Pazo; Yue Ren; Li-Jun Shen
Journal:  Int J Ophthalmol       Date:  2022-05-18       Impact factor: 1.779

5.  Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy.

Authors:  Ekta Rishi; Pukhraj Rishi; Sheshadri Mahajan
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

6.  New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy.

Authors:  D Marchant; K Yu; K Bigot; O Roche; A Germain; D Bonneau; V Drouin-Garraud; D F Schorderet; F Munier; D Schmidt; P Le Neindre; C Marsac; M Menasche; J L Dufier; R Fischmeister; C Hartzell; M Abitbol
Journal:  J Med Genet       Date:  2007-02-07       Impact factor: 6.318

7.  Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab.

Authors:  Jörg Leu; Norbert F Schrage; Robert F Degenring
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-29       Impact factor: 3.117

8.  Atypical vitelliform macular dystrophy misdiagnosed as chronic central serous chorioretinopathy: case reports.

Authors:  Young Seob Lee; Eung-Suk Kim; Moosang Kim; Young-Gyun Kim; Hyung-Woo Kwak; Seung-Young Yu
Journal:  BMC Ophthalmol       Date:  2012-07-20       Impact factor: 2.209

9.  BEST1 sequence variants in Italian patients with vitelliform macular dystrophy.

Authors:  Andrea Sodi; Ilaria Passerini; Vittoria Murro; Roberto Caputo; Giacomo Maria Bacci; Mirela Bodoj; Francesca Torricelli; Ugo Menchini
Journal:  Mol Vis       Date:  2012-11-17       Impact factor: 2.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.